Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses

New vaccine platforms are needed to address the time gap between pathogen emergence and vaccine licensure. RNA-based vaccines are an attractive candidate for this role: they are safe, are produced cell free, and can be rapidly generated in response to pathogen emergence. Two RNA vaccine platforms ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogel, Annette B., Lambert, Laura, Kinnear, Ekaterina, Busse, David, Erbar, Stephanie, Reuter, Kerstin C., Wicke, Lena, Perkovic, Mario, Beissert, Tim, Haas, Heinrich, Reece, Stephen T., Sahin, Ugur, Tregoning, John S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835025/
https://www.ncbi.nlm.nih.gov/pubmed/29275847
http://dx.doi.org/10.1016/j.ymthe.2017.11.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835025/
https://www.ncbi.nlm.nih.gov/pubmed/29275847
http://dx.doi.org/10.1016/j.ymthe.2017.11.017

Ejemplares similares